ERN ReCONNET WP3 STEP3 MEETING REPORT

 In Uncategorized

5th November 2017 | Hotel Hilton Bayfront, San Diego, USA

Introduction

After the ERN ReCONNET Meeting held in Madrid during the EULAR 2017 congress, the members of the Network met again on 5th November 2017 at the Hotel Hilton Bayfront in San Diego, during the ACR 2017 annual meeting.

The meeting main objectives were:

  • Presentation of WP3 Step 3 Preliminary results (existing guidelines assessment)
  • Preliminary discussion on WP3 Step 4 (identification of unmet needs and gaps in existing guidelines)

WP3 Preliminary results presentation and discussion

Marta Mosca has briefly overviewed the 5 years working plan of ERN ReCONNET, the 1st year workplan and deliverables and WP3. In detail WP3 aims at the identification and, eventually, development of recommendations and guidelines.

The literature review has been concluded and recommendations have been reviewed following the AGREE tool as a guide.

Disease coordinators have reported on the results of the literature review together with a list of unmet needs identified during the first steps.

General discussion, comments, suggestions

The literature review has highlighted the absence of evidence-based recommendations for some diseases.

This might be explained by the absence of data to support the development of these recommendations and highlights the need of future studies which could be supported by the ERN ReCONNET in collaborations with study groups/scientific societies.

The aim of the ERN ReCONNET is not to develop guidelines, but rather to collaborate with study groups and scientific societies in the process of developing, reviewing, adapting and implementing guidelines. A collaborative strategy will be discussed by the Steering committee after the review of the literature will be completed.

Next Steps

The STEP 5 is a final Official Report on the evaluation of existing guidelines, edited from the ERN ReCONNET Coordinator, in which all the results of WP3 will be collected, elaborated and sent to the European Commission.